BidaskClub downgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a report published on Saturday.
A number of other analysts have also weighed in on INGN. Zacks Investment Research upgraded Inogen from a hold rating to a strong-buy rating and set a $214.00 target price on the stock in a research note on Monday, July 2nd. Piper Jaffray Companies increased their target price on Inogen to $235.00 and gave the stock an overweight rating in a research note on Monday, July 9th. Needham & Company LLC increased their target price on Inogen from $215.00 to $254.00 and gave the stock a strong-buy rating in a research note on Wednesday, August 8th. Finally, Stifel Nicolaus set a $258.00 target price on Inogen and gave the stock a buy rating in a research note on Tuesday, August 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Inogen currently has an average rating of Buy and an average price target of $247.33.
Shares of INGN opened at $191.16 on Friday. The firm has a market capitalization of $4.00 billion, a P/E ratio of 144.43, a P/E/G ratio of 3.70 and a beta of 1.26. Inogen has a 52-week low of $96.82 and a 52-week high of $287.79.
In other Inogen news, insider Matt Scribner sold 2,000 shares of the stock in a transaction on Monday, September 17th. The stock was sold at an average price of $281.23, for a total value of $562,460.00. Following the sale, the insider now owns 7,595 shares in the company, valued at $2,135,941.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Raymond Huggenberger sold 10,500 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $196.62, for a total value of $2,064,510.00. Following the transaction, the director now owns 8,797 shares in the company, valued at approximately $1,729,666.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,953 shares of company stock worth $17,231,375. Insiders own 5.29% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC increased its stake in shares of Inogen by 52.8% during the third quarter. Acadian Asset Management LLC now owns 84,279 shares of the medical technology company’s stock valued at $20,573,000 after buying an additional 29,124 shares during the period. Oregon Public Employees Retirement Fund purchased a new position in shares of Inogen during the third quarter valued at $854,000. FNY Investment Advisers LLC increased its stake in shares of Inogen by 41,775.0% during the third quarter. FNY Investment Advisers LLC now owns 6,700 shares of the medical technology company’s stock valued at $1,634,000 after buying an additional 6,684 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in shares of Inogen during the third quarter valued at $324,000. Finally, State Treasurer State of Michigan purchased a new position in shares of Inogen during the third quarter valued at $1,562,000. Hedge funds and other institutional investors own 96.65% of the company’s stock.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Article: The Discount Rate – What You Need to Know
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.